linjc16/ctgov huggingface dataset:
Correlation Between Maximal Inspiratory Pressure and Hand Grip Force

Study Overview
=================
Brief Summary
-----------------
This study aimed to examine the possible relationship between hand grip strength (HGS) and maximum inspiratory pressure (MIP) in healthy individuals.

Detailed Description
-----------------
This study aimed to examine the possible relationship between hand grip strength (HGS) and maximum inspiratory pressure (MIP) in healthy individuals. All individuals underwent assessment of inspiratory muscle strength by maximum inspiratory pressure, and evaluation of hand grip strength. MIP was measured using a U-type water manometer calibrated in centimetre of water (cmH2O), while the HGS was measured with hydraulic hand dynamometer calibrated in Kg.

Official Title
-----------------
Correlation Between Maximal Inspiratory Pressure and Hand Grip Force in Healthy Individuals

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Other: Healthy individuals


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy individuals Exclusion Criteria: age <20 years old, pregnancy, official diagnosis with lung disease such as Chronic obstructive pulmonary disease (COPD), body mass index (BMI) > 40, known pre-existing causes of neuromuscular weakness, median entrapment neuropathy such as carpal tunnel syndrome

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Healthy individuals<br>Study population was consisted by healthy volunteers from hospital staff of physical therapy department, Intensive Care Unit, and cleaning service. All subjects were men and women aged between 20 and 65 years old, who never had major problems with the respiratory system or with the hand flexors. | Other: Healthy individuals<br>* INSPIRATORY PRESSURE AND HAND GRIP FORCE CORRELATION<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| CORRELATION BETWEEN MAXIMAL INSPIRATORY PRESSURE AND HAND GRIP FORCE | MIP was measured using a U-type water manometer calibrated in cmH2O, while the HGS was measured with hydraulic hand dynamometer calibrated in Kg. | one month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
MIP, Hand Grip, Correlation, Inspiratory Pressure, Hand Grip Force
Bed-rest, Muscle Mass and Insulin Sensitivity

Study Overview
=================
Brief Summary
-----------------
In the present study, the effects of 7 days of bed rest on muscle mass, muscle fiber characteristics and insulin sensitivity will be determined.

Official Title
-----------------
The Impact of Short-term Bed-rest on Skeletal Muscle Mass and Insulin Sensitivity in Healthy, Young Men

Conditions
-----------------
Disuse Atrophy

Intervention / Treatment
-----------------
* Behavioral: Bed rest


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male Aged from 18-35 years 18.5 < BMI < 30 kg/m2 Exclusion Criteria: Smoking Performing regular resistance training (3+ times per week, carrying out progressive training) in the previous 6 months Hypertension (according to WHO criteria) and/or cardiovascular disease Any back/leg/knee/neck/postural complaints Use of any prescribed medication Type 2 diabetes mellitus Any family history of thrombosis All co-morbidities interacting with mobility and muscle metabolism of the lower limbs (e.g. arthritis, spasticity/rigidity, all neurological disorders and paralysis). Myocardial infarction within the last 3 years Use of anti-coagulants

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Bed rest<br>One week of bed rest. | Behavioral: Bed rest<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in quadriceps muscle cross-sectional area |  | One day before and directly after cessation of bed rest. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in lower back cross-sectional area |  | One day before and directly after cessation of bed rest. | 
| Change in leg and whole body lean tissue mass |  | One day before and directly after cessation of bed rest. | 
| Change in muscle fiber size |  | One day before and directly after cessation of bed rest. | 
| Change in muscle strength | Measured by 1-Repetition Maximum testing | One day before and directly after cessation of bed rest. | 
| Change in insulin sensitivity | Measured by hyperinsulinemic-euglycemic clamp | One day before and directly after cessation of bed rest. |
Phase I Vorinostat Concurrent With Stereotactic Radiosurgery (SRS) in Brain Metastases From Non-Small Cell Lung Cancer

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the maximum tolerated dose (MTD) of vorinostat given concurrently with stereotactic radiosurgery (SRS) to treat non-small cell lung cancer (NSCLCA) brain metastases in patient with 1-4 lesions.

Official Title
-----------------
A Phase I Trial of Vorinostat Concurrent With Stereotactic Radiotherapy in Treatment of Brain Metastases From Non-Small Cell Lung Cancer

Conditions
-----------------
Brain Cancer, Neoplasm Metastasis, Lung Cancer, Carcinoma, Non-Small-Cell Lung

Intervention / Treatment
-----------------
* Drug: Vorinostat
* Procedure: Radiation Therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients age 18 years and older with histologically proven non-small cell lung cancer and 1-4 brain metastases, each measuring less than 2 cm will be eligible. Prior surgery or radiation is allowed as long as the target metastatic lesion(s) has not been treated with previous radiation. Adequate organ function (section 3.1.10). ECOG performance status 0-2. Life expectancy of >=12 weeks. Systemic chemotherapy washout period >=7 days. Exclusion Criteria: Patients who have previously been treated with whole brain irradiation, pediatric patients (age <18), pregnant women, and patients who are unable to give informed consent.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: vorinostat & stereotactic radiosurgery<br> | Drug: Vorinostat<br>* Orally up to 400 mg<br>Procedure: Radiation Therapy<br>* Single fraction stereotactic radiotherapy - Standard of Care<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The maximum tolerated dose of vorinostat with concurrent radiosurgery will be determined. |  | 30 days following Stereotactic Radiosurgery | 
| During the expanded phase I portion of the study, the safety of the Maximum tolerated dose dose will be confirmed. |  | 30 days following Stereotactic Radiosurgery | 
| The radiologic response, defined as local control and distant intra-cranial control rates at 3-months following radiotherapy, will be determined. |  | 3 months following Stereotactic Radiosurgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The short-term (< 30 days post-treatment) and long-term (> 30 days post-treatment) adverse effects will be determined. |  | 12 months | 
| The 12-month survival rate from the date of Stereotactic Radiosurgery will be determined. |  | 12 months |
Pulsed Dye Laser for the Psoriatic Nail

Study Overview
=================
Brief Summary
-----------------
The treatment options for nail psoriasis have been limited, and the management of nail psoriasis has been challenging for physicians.To evaluate the effect of pulsed dye laser (PDL) in the treatment of nail psoriasis.

Detailed Description
-----------------
Psoriatic nails of patient's right hand were treated using PDL (595 nm) .The pulsed duration is 1.5ms, the beam diameter is 7mm, and the laser energy is 8.0 to 10.0 J/cm2. The treatment course of pulse dye laser is once monthly for 6 months. Psoriatic nails of both hands are treated with Tazarotene cream for 6 months. Clinical efficacy is statistically evaluated according to Nail Psoriasis Severity Index (NAPSI) score differences between right and left hand one month after 3rd and 6th therapy.

Official Title
-----------------
Pulsed Dye Laser for the Psoriatic Nail

Conditions
-----------------
Psoriatic Nail

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Psoriatic nail refractory to other topical and systemic treatment therapy ≧ 16 years old Exclusion Criteria: Patient with pregnancy Patient with photo sensitivity Patient with severe wound around finger nails or paronychia Patient with hypersensitivity to Tazarotene cream

Ages Eligible for Study
-----------------
Minimum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental Group<br> | |
| Control Group<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| NAPSI |  | 3rd and 6th months | 
| global physician assessment |  | 3rd and 6th months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Psoriatic Nail, Pulsed dye laser
RCT: STARR vs Biofeedback

Study Overview
=================
Brief Summary
-----------------
This study aimed to evaluate the safety and symptomatic outcomes achieved with Stapled Transanal Rectal Resection (STARR) compared to biofeedback training in patients with obstructed defecation syndrome (ODS).

Official Title
-----------------
Outcomes of Stapled Trans-Anal Rectal Resection (STARR) vs. Biofeedback in the Treatment of Outlet Obstruction Associated With Rectal Intussusception and Rectocele: A Multi-center Randomized Controlled Trial

Conditions
-----------------
Anismus, Gastric Outlet Obstruction, Rectocele, Intussusception

Intervention / Treatment
-----------------
* Device: STARR
* Behavioral: Biofeedback


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Female patients >18 years old Able to comprehend, follow, and provide written informed consent. Minimum ODS Score of seven at screening. Negative pregnancy test, by urine. 'Obstructed' defecation requiring straining/digitation as presenting lead symptom. Adequate external sphincter on rectal digital examination. Evidence of anterior rectocele and/or rectal intussusception on dynamic defecography. (Note: dynamic defecography taken within 12 months will be acceptable) Willingness to comply with study requirements including follow-up visits Exclusion Criteria: Evidence of external sphincter injury associated with incontinence. Enterocele at rest- requiring surgery. Faecal incontinence (soiling and faecal urgency is admissible). Any anterior defect, colpocele or cystocele requiring a combined surgical approach. Physical or psychological condition which would impair participation in the study. Participation in any other device or drug study within 90 days prior to enrollment. Planned participation in any other device study during the timeframe of this study. General contraindication for surgery. Previous transanal surgery for ODS. Immunocompromised subjects

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>STARR | Device: STARR<br>* Stapled Trans-Anal Rectal Resection for the treatment of ODS<br>|
| Active Comparator: 2<br>Biofeedback | Behavioral: Biofeedback<br>* electromyographic-based treatment sessions<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ODS total score |  | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PAC-QoL score |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
outlet obstruction, rectocele
Prevalence and Clinical Significance of Anti-annexin A2 Antibodies in COVID-19 Infection

Study Overview
=================
Brief Summary
-----------------
In January 2020, researchers isolated and sequenced in China from patients with severe atypical pneumonia a novel coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 has rapidly spread throughout the world. SARS-CoV-2 may trigger hyperstimulation of immune system with an autoinflammatory response but also the development of an autoimmune process. These autoimmune responses may also develop through the molecular mimicry between virus and human-self components. Multiple autoantibodies have been described in COVID-19 patients. Annexin A2 (ANXA2), an endothelial cell receptor for plasminogen and tissue plasminogen activator has been identified as a new autoantigen in antiphospholipid syndrome. ANXA2 has been identified as candidate autoantigen recognized by SARS patient sera. ANXA2 contributes also to pulmonary microvascular integrity. These data lead to identify anti-ANXA2 antibodies in COVID-19 patient sera and to know if the presence of these antibodies is associated with pulmonary injury or thrombosis in COVID-19 and represents a marker of severity.

Official Title
-----------------
Prevalence and Clinical Significance of Anti-annexin A2 Antibodies in COVID-19 Infection

Conditions
-----------------
COVID-19

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years and older All patients hospitalized in Amiens University Hospital with COVID-19 infection Exclusion Criteria: Autoimmune diseases Chronic viral infection by hepatitis B virus, hepatitis C virus or human immunodeficiency virus (HIV) Immunosuppressive treatment Solid tumors Hematological malignancies

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of anti-ANXA2 antibodies in patients with COVID-19 infection |  | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
COVID-19, annexin A2
Recovery After Robotic Urogynecological Surgery: The Patient's Perspective

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to describe the patient experience, including pain scores, use of pain medications, resumption of usual activities, and bowel function in the post-operative period following robotic urogynecologic surgery. Additionally, to describe peri-operative parameters of robot-assisted urogynecologic surgery.

Official Title
-----------------
Recovery After Robotic Urogynecological Surgery: The Patient's Perspective

Conditions
-----------------
Urogynecology

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women who underwent DaVinci-assisted laparoscopic surgery Completion of a post-operative quality assurance questionnaire from 09/2007 - 09/2008 Exclusion Criteria: Any women not meeting above inclusion criteria

Ages Eligible for Study
-----------------
Minimum Age: 21 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
LUNG FIBROTIC CHANGES ASSOCIATED WITH SARS-CoV-2 INFECTION

Study Overview
=================
Brief Summary
-----------------
Prospective, observational, multicenter study that will evaluate the changes in lung function that patients admitted with SARS-CoV-2 pneumonia will present according to the level of severity at 4, 12, 26 and 52 weeks after hospital discharge.

Detailed Description
-----------------
The project consists of a prospective, observational, multicenter study that will evaluate changes in lung function (forced spirometry, measurement of static lung volumes using plethysmography and pulmonary carbon monoxide diffusion test) that patients admitted with pneumonia will present. caused by SARS-CoV-2 according to the level of severity at 4, 12, 26 and 52 weeks after discharge from hospital. Restrictive pulmonary abnormalities will be confirmed by imaging tests (high resolution chest CT).

Official Title
-----------------
STUDY OF THE APPEARANCE OF LUNG FIBROTIC CHANGES ASSOCIATED WITH SARS-CoV-2 INFECTION

Conditions
-----------------
Pulmonary Fibrosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients admitted for bilateral pneumonia caused by SARS-CoV-2 (confirmed by PCR). Age over 18 years. Acceptance of informed consent. Life expectancy over 1 year. Exclusion Criteria: Patients with a previous diagnosis of interstitial lung disease. Inability to attend review visits.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pulmonary fibrotic changes, short and medium term | To analyze the number of patients who will develop pulmonary fibrotic changes, in the short and medium term, after surviving a bilateral pulmonary infection by SARS-CoV-2 | 12 months | 
| Degree of lung function impairment | To study the degree of lung function impairment, specifically the restrictive changes in functional capacity and diffusion alterations and its relationship with clinical variables. | 6 and 12 months | 
| Biological markers | Examine the biological markers in the patients who will present this dysregulation of the curative response that will give rise to pulmonary fibrosing phenomena. | 1 month |
Assesment of the Efficacy of Personalized Parent-child Psychotherapy in Children Under 3 Years Old

Study Overview
=================
Brief Summary
-----------------
This study aims to assess the efficacy at 4 months of a personalized strategy comparatively to a standard Psychodynamic Integrative Therapy, on childrens' symptom improvment

Detailed Description
-----------------
3 evaluations are performed: before treatment, at the end of the treatment and one year after the treatment. evaluations include assessment of: children's symptom parent-infant interaction quality parental competencies parental perception of the child by his/her parent parent-therapist alliance hair cortisol concentration

Official Title
-----------------
Assesment of the Efficacy of Personalized Parent-child Psychotherapy Evaluating Symptoms in Children Under 3 Years Old and Parent-child Interaction.

Conditions
-----------------
Child Behavior Disorders, Parent-Child Relations

Intervention / Treatment
-----------------
* Behavioral: Personalized psychotherapy
* Behavioral: Standard of care


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Families who are requesting a consultation for functional or behavioural problems of their child Children under the age of 3 Exclusion Criteria: Parents suffering from a severe untreated psychiatric disorder Difficulties in speaking French Children with Autistic spectrum disorder Families already in care

Ages Eligible for Study
-----------------
Maximum Age: 3 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Standard care group<br>Standard psychodynamic therapy | Behavioral: Standard of care<br>* Strategy based standard intregrative psychodynamic therapy<br>* Other names: Standard intregrative psychodynamic therapy;|
| Experimental: Personalized care<br>Psychodynamic therapy or interactive guidance therapy | Behavioral: Personalized psychotherapy<br>* Strategy including personalized psychotherapy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficacy of therapy | To assess the efficacy at 4 months of a personalized strategy by Interactive Guidance or Psychodynamic Therapy, comparatively to a standard Psychodynamic Therapy, on child symptoms assessed with the Symptom Check List | Month 4 |